Markets believe AstraZeneca can continue to deliver strong double-digit growth in 2022, but will the pharma giant’s outlook meet expectations this week?
Pfizer’s revenue and earnings have soared thanks to strong demand for its coronavirus vaccine, but there are concerns there could be a significant slowdown in 2022. We explain what to expect and consider how Pfizer shares could react.